Study #2015-1040
Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) with Dasatinib and Venetoclax: A Phase II Study
MD Anderson Study Status
Not Accepting
Treatment Agent
Dasatinib, Venetoclax
Description
This phase II trial studies how well dasatinib and venetoclax work in treating patients with Philadelphia chromosome positive or BCR-ABL1 positive early chronic phase chronic myelogenous leukemia. Dasatinib and venetoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
Study phase:
Phase II
Physician name:
Elias Jabbour
Department:
Leukemia
For general questions about clinical trials:
1-844-866-3603
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.